Although effective, opioid agonist therapy is associated with stigma and thus underutilized for treatment of opioid use disorder in incarcerated settings.
AMA J Ethics. 2017;19(9):922-930. doi:
10.1001/journalofethics.2017.19.9.stas1-1709.
Targeted dosing to treat pediatric inflammatory bowel disease is challenging because dosing guidelines are based on data gathered from adult subjects of clinical trials. Patients’ families and health care organizations also incur high costs and must try to balance potential benefits against risks of ongoing monitoring.
AMA J Ethics. 2018;20(9):E841-848. doi:
10.1001/amajethics.2018.841.